Abstract
AbstractImmunocompromised patients are predisposed to severe COVID-19. Here we compare homotypic and heterotypic humoral and cellular immune responses to Omicron BA.1 in organ transplant patients across a diverse clinical spectrum. We perform variant-specific pseudovirus neutralization assays for D614G, and Omicron-BA.1, -BA.2, and Delta variants. We also measure poly-and monofunctional T-cell responses to BA.1 and ancestral SARS-CoV-2 peptide pools. We identify that partially or fully-vaccinated transplant recipients after infection with Omicron BA.1 have the greatest BA.1 neutralizing antibody and BA.1-specific polyfunctional CD4+ and CD8+ T-cell responses, with potent cross-neutralization against BA.2. In these patients, the magnitude of the BA.1-directed response is comparable to immunocompetent triple-vaccinated controls. A subset of patients with pre-Omicron infection have heterotypic responses to BA.1 and BA.2, whereas uninfected transplant patients with three doses of vaccine demonstrate the weakest comparative responses. These results have implications for risk of infection, re-infection, and disease severity among immune compromised hosts with Omicron infection.
Funder
Public Health Agency of Canada
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference34 articles.
1. Goldman, J. D., Robinson, P. C., Uldrick, T. S. & Ljungman, P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J. Immunother. Cancer. 9, e002630 (2021).
2. Marinelli, T. et al. Prospective clinical, virologic, and immunologic assessment of COVID-19 in transplant recipients. Transplantation 105, 2175–83 (2021).
3. Pereira, M. R. et al. Outcomes of COVID-19 in solid organ transplant recipients: a matched cohort study. Transpl. Infect. Dis. 23, e13637 (2021).
4. Hall, V. G. et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N. Engl. J. Med. 385, 1244–1246 (2021).
5. Werbel, W. A. et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann. Intern. Med. 174, 1330–1332 (2021).